- RecruitingPHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
This study, called iFIT, helps doctors find the best treatments for older myeloma patients. It checks how well standard NHS treatment works and looks at your fitness level. Then, it uses this information to decide the next steps, aiming to improve your care.
For: Multiple Myeloma (MM) · Plasma Cell Leukemia (PCL)United Kingdom - RecruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
For: Multiple MyelomaGermany - Active not recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
This study is looking for ways to prevent or reduce changes in taste that can be a side effect of medicines like talquetamab and ramantamig, which are used to treat a type of cancer called multiple myeloma.
For: Multiple MyelomaUnited States · Brazil · Netherlands - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is looking into two new medicines, talquetamab and teclistamab, for people with multiple myeloma that has come back or isn't responding to other treatments. It aims to find the safest and most effective way to use them together, especially for those with hard-to-treat forms of the disease.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, talquetamab, for people with multiple myeloma that has come back or isn't responding to other treatments. The main goal is to see how well it works and if it's safe at the recommended doses.
For: Hematological MalignanciesUnited States · Belgium · China - Active not recruitingPHASE1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
This study looks at new ways to treat a blood cancer called multiple myeloma. It combines an existing medicine, Daratumumab, with newer ones (Talquetamab or Teclistamab), sometimes with Pomalidomide. The main goal is to find safe doses and see how well these combinations work.
For: Multiple MyelomaUnited States · Canada · Germany - Active not recruitingPHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This study looks at new treatments for younger adults with newly diagnosed multiple myeloma. It tests combinations of medications like teclistamab and talquetamab, depending on whether a small amount of cancer is still present after initial treatment. The goal is to find better ways to manage the disease.
For: Multiple MyelomaFrance - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is looking at a new medicine called talquetamab, combined with other treatments, for people with multiple myeloma. The main goal is to find safe doses and understand how well these combinations work together.
For: Multiple MyelomaUnited States · Australia · Belgium - Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
This study looks at how well new treatments called teclistamab and talquetamab work for people in the UK with a specific type of blood cancer called multiple myeloma, when these treatments are given outside of formal clinical trials. It's about understanding real-world results.
For: Relapsed/Refractory Multiple Myeloma (RRMM)Denmark · France · Germany - Active not recruitingPHASE3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
This study looks at new drug combinations for multiple myeloma that has come back or isn’t responding to treatment. It compares a drug called talquetamab, alone or with another drug called daratumumab, against a standard treatment of daratumumab, pomalidomide, and dexamethasone.
For: Multiple MyelomaUnited States · Belgium · Brazil